U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H13N5O4
Molecular Weight 255.2306
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GANCICLOVIR

SMILES

NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1

InChI

InChIKey=IRSCQMHQWWYFCW-UHFFFAOYSA-N
InChI=1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17)

HIDE SMILES / InChI

Molecular Formula C9H13N5O4
Molecular Weight 255.2306
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/monograph/valganciclovir-hydrochloride.html | http://www.rxlist.com/valcyte-drug/indications-dosage.htm

There is no information in the literature about pharmacological and biological application of definite isomer: R of valganciclovir. However, is known, that valganciclovir, existing, as a mixture of R and S diasteriomers, is the active ingredient in Valcyte, which is used as an antiviral medication given to patients who have a high chance of developing cytomegalovirus (CMV) disease after receiving a heart, kidney, or kidney-pancreas transplant. It was proposed, that stable aqueous solutions of valganciclovir can be prepared in aqueous solutions at acidic pHs but these solutions will exist as a mixture of isomers: R and S

Originator

Curator's Comment: The first synthesis of ganciclovir was reported by Julien Verheyden and John Martin at Syntex Research in California in 1980 and is marketed as sodium salt (Ganciclovir sodium) under the trade names Cytovene and Cymevene.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P08546
Gene ID: NA
Gene Symbol: UL54
Target Organism: Human cytomegalovirus (strain AD169) (HHV-5) (Human herpesvirus 5)
0.08 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ZIRGAN

Approved Use

ZIRGAN is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).

Launch Date

8.1362878E11
Primary
CYTOVENE

Approved Use

CYTOVENE-IV is indicated for the treatment of CMV retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). CYTOVENE-IV is also indicated for the prevention of CMV disease in transplant recipients at risk for CMV disease.

Launch Date

7.8805441E11
Primary
VALCYTE

Approved Use

VALCYTE is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS)

Launch Date

9.8573759E11
Primary
VALCYTE

Approved Use

VALCYTE is indicated for the prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk

Launch Date

9.8573759E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4.8 mg/L
1 g 3 times / day multiple, oral
dose: 1 g
route of administration: Oral
experiment type: MULTIPLE
co-administered:
GANCICLOVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
13.3 μg/mL
5 mg/kg single, intravenous
dose: 5 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GANCICLOVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
35.4 mg × h/L
1 g 3 times / day multiple, oral
dose: 1 g
route of administration: Oral
experiment type: MULTIPLE
co-administered:
GANCICLOVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
53.8 μg × h/mL
5 mg/kg single, intravenous
dose: 5 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GANCICLOVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.2 h
5 mg/kg single, intravenous
dose: 5 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GANCICLOVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1000 mg 6 times / day multiple, oral
Highest studied dose
Dose: 1000 mg, 6 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 6 times / day
Sources:
unhealthy, 37.4
n = 19
Health Status: unhealthy
Condition: AIDS
Age Group: 37.4
Population Size: 19
Sources:
2000 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2000 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2000 mg, 3 times / day
Sources:
unhealthy, 38.6
n = 50
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: 38.6
Population Size: 50
Sources:
Other AEs: Neutropenia, Thrombocytopenia...
Other AEs:
Neutropenia (18%)
Thrombocytopenia (4%)
Anemia (severe, 4%)
Renal impairment (4%)
Sources:
50 mg/kg 3 times / day multiple, oral
Highest studied dose
Dose: 50 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg/kg, 3 times / day
Sources:
unhealthy, 7.4 years (range: 0.5-16.9 years)
n = 36
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: 7.4 years (range: 0.5-16.9 years)
Population Size: 36
Sources:
Other AEs: Neutropenia...
Other AEs:
Neutropenia (22%)
Sources:
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Other AEs: Fever, Infection...
Other AEs:
Fever (48%)
Infection (13%)
Chills (10%)
Sepsis (15%)
Diarrhea (44%)
Anorexia (14%)
Vomiting (13%)
Leukopenia (41%)
Anemia (25%)
Thrombocytopenia (6%)
Neuropathy (9%)
Sweating (12%)
Pruritus (5%)
Catheter infection (9%)
Catheter sepsis (8%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Neutropenia 18%
2000 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2000 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2000 mg, 3 times / day
Sources:
unhealthy, 38.6
n = 50
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: 38.6
Population Size: 50
Sources:
Renal impairment 4%
2000 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2000 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2000 mg, 3 times / day
Sources:
unhealthy, 38.6
n = 50
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: 38.6
Population Size: 50
Sources:
Thrombocytopenia 4%
2000 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2000 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2000 mg, 3 times / day
Sources:
unhealthy, 38.6
n = 50
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: 38.6
Population Size: 50
Sources:
Anemia severe, 4%
2000 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2000 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2000 mg, 3 times / day
Sources:
unhealthy, 38.6
n = 50
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: 38.6
Population Size: 50
Sources:
Neutropenia 22%
50 mg/kg 3 times / day multiple, oral
Highest studied dose
Dose: 50 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg/kg, 3 times / day
Sources:
unhealthy, 7.4 years (range: 0.5-16.9 years)
n = 36
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: 7.4 years (range: 0.5-16.9 years)
Population Size: 36
Sources:
Chills 10%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Sweating 12%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Infection 13%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Vomiting 13%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Anorexia 14%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Sepsis 15%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Anemia 25%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Leukopenia 41%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Diarrhea 44%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Fever 48%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Pruritus 5%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Thrombocytopenia 6%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Catheter sepsis 8%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Catheter infection 9%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Neuropathy 9%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
PubMed

PubMed

TitleDatePubMed
Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients.
1999
Ganciclovir-induced encephalopathy in a bone marrow transplant recipient.
1999 Aug
Hydroxyurea potentiates the antiherpesvirus activities of purine and pyrimidine nucleoside and nucleoside phosphonate analogs.
1999 Dec
Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir.
1999 Oct
Human cytomegalovirus: challenges, opportunities and new drug development.
1999 Sep
Posttransplantation: emerging and future therapies.
2000
Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase.
2000 Oct
Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients.
2000 Oct
Guanosine analogues as anti-herpesvirus agents.
2000 Oct-Dec
Prophylaxis against herpesvirus infections in transplant recipients.
2001
Suspension of anticytomegalovirus maintenance therapy following immune recovery due to highly active antiretroviral therapy.
2001 Apr
Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality.
2001 Apr 1
Adenoviral-mediated gene therapy for thyroid carcinoma using thymidine kinase controlled by thyroglobulin promoter demonstrates high specificity and low toxicity.
2001 Feb
Genetic risks of antiviral nucleoside analogues--a survey.
2001 Feb
Failure of cidofovir to reduce CMV-antigenemia in a child transplanted from a matched unrelated donor.
2001 Feb
Coexistent cutaneous Aspergillus and cytomegalovirus infection in a liver transplant recipient.
2001 Feb
Rhodococcus equi and cytomegalovirus pneumonia in a renal transplant patient: diagnosis by fine-needle aspiration biopsy.
2001 Feb
Mutation of Gln125 to Asn selectively abolishes the thymidylate kinase activity of herpes simplex virus type 1 thymidine kinase.
2001 Feb
Construction of gene therapy vectors targeting thyroid cells: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3',5'-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cells.
2001 Feb
Stimulation of intercellular communication of poor-communicating cells by gap-junction-competent cells enhances the HSV-TK/GCV bystander effect in vitro.
2001 Feb 15
Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations.
2001 Feb 15
Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes.
2001 Feb 15
Cytomegalovirus infection-enhanced chronic rejection in the rat is prevented by antiviral prophylaxis.
2001 Feb-Mar
Ganciclovir prophylaxis for cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone.
2001 Feb-Mar
Epstein-Barr virus encephalitis in a renal allograft recipient diagnosed by polymerase chain reaction on cerebrospinal fluid and successfully treated with ganciclovir.
2001 Jan
Imaging in vivo herpes simplex virus thymidine kinase gene transfer to tumour-bearing rodents using positron emission tomography and.
2001 Jan
[Gene therapy for colorectal cancer].
2001 Jan
[Perspectives on postgenome medicine: Gene therapy for brain tumors].
2001 Jan
In vitro effects of antiviral agents on human keratocytes.
2001 Jan
Isolation and analysis of an aciclovir-resistant murine cytomegalovirus mutant.
2001 Jan
Gene therapy for hepatocellular carcinoma based on tumour-selective suicide gene expression using the alpha-fetoprotein (AFP) enhancer and a housekeeping gene promoter.
2001 Jan
Disseminated cytomegalovirus disease in hosts without acquired immunodeficiency syndrome and without an organ transplant.
2001 Jan 15
Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation.
2001 Jan 15
Human beta-herpesvirus interactions in solid organ transplant recipients.
2001 Jan 15
Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis.
2001 Mar
High-dose intravitreal ganciclovir and foscarnet for cytomegalovirus retinitis.
2001 Mar
Frosted branch angiitis in a child with HIV infection.
2001 Mar
New developments in the management of cytomegalovirus infection and disease after renal transplantation.
2001 Mar
Gene therapy for hepatocellular carcinoma using two recombinant adenovirus vectors with alpha-fetoprotein promoter and Cre/lox P system.
2001 Mar
Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus.
2001 Mar 1
Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients.
2001 Mar 1
Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation.
2001 Mar-Apr
The Role of Antiviral Prophylaxis for the Prevention of Epstein-Barr Virus-Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review.
2017 Mar
A 42-Year-Old Woman With Anemia, Shock, and Ischemic Stroke After Lung Transplantation.
2017 Mar
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Ganciclovir can be used as ophthalmic gel 1 drop in the affected eye 5 times per day in patients with acute herpetic keratitis.
Induction: The recommended dosage is 900 mg (two 450 mg tablets) taken orally twice a day for 21 days. Maintenance: Following induction treatment, or in adult patients with inactive CMV retinitis, the recommended dosage is 900 mg (two 450 mg tablets) taken orally once a day.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: The median concentration of ganciclovir that inhibits CMV replication (IC50) in vitro (laboratory strains or clinical isolates) has ranged from 0.02 to 3.48 ug/mL.
Ganciclovir inhibits mammalian cell proliferation (CIC50) in cell culture at higher concentrations ranging from 40 to > 1000 uM (10.21 to > 250 ug/mL). Bone marrow-derived colony-forming cells are more sensitive [CIC50 = 2.7 to 12 uM (0.69 to 3.06 ug/mL)].
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:36:20 UTC 2023
Edited
by admin
on Wed Jul 05 22:36:20 UTC 2023
Record UNII
P9G3CKZ4P5
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GANCICLOVIR
EMA EPAR   EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
BW 759U
Code English
GANCICLOVIR [HSDB]
Common Name English
GANCICLOVIR [EP IMPURITY]
Common Name English
GANCICLOVIR [EMA EPAR]
Common Name English
9-[[2-Hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine
Systematic Name English
Ganciclovir [WHO-DD]
Common Name English
VALGANCICLOVIR HYDROCHLORIDE IMPURITY A [USP IMPURITY]
Common Name English
GANCICLOVIR [USAN]
Common Name English
GANCICLOVIR [USP MONOGRAPH]
Common Name English
6H-PURIN-6-ONE, 2-AMINO-1,9-DIHYDRO-9-((2-HYDROXY-1-(HYDROXYMETHYL)ETHOXY)METHYL)-
Systematic Name English
GANCICLOVIR [MART.]
Common Name English
VITRASERT
Brand Name English
ZIRGAN
Brand Name English
GANCICLOVIR [ORANGE BOOK]
Common Name English
RS-21592
Code English
BW-759U
Code English
ganciclovir [INN]
Common Name English
GANCICLOVIR [EP MONOGRAPH]
Common Name English
GANCICLOVIR [VANDF]
Common Name English
NSC-759656
Code English
GANCICLOVIR [MI]
Common Name English
GANCICLOVIR [USP-RS]
Common Name English
GANCICLOVIR [JAN]
Common Name English
GANCYCLOVIR
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 237607
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
NCI_THESAURUS C1556
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
NCI_THESAURUS C29575
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
EMA ASSESSMENT REPORTS VITRASERT IMPLANT (WITHDRAWN: HIV INFECTIONS)
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
NDF-RT N0000020060
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
LIVERTOX NBK548760
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
NDF-RT N0000175461
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
EMA ASSESSMENT REPORTS VITRASERT IMPLANT (WITHDRAWN: CYTOMEGALOVIRUS RETINITIS)
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
NDF-RT N0000175466
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
WHO-VATC QS01AD09
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
FDA ORPHAN DRUG 5885
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
NDF-RT N0000175459
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
NCI_THESAURUS C281
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
WHO-ATC J05AB06
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
WHO-VATC QJ05AB06
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
NDF-RT N0000175459
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
WHO-ATC S01AD09
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
FDA ORPHAN DRUG 86494
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
NDF-RT N0000175459
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
Code System Code Type Description
CHEBI
465284
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
PRIMARY
SMS_ID
100000085455
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
PRIMARY
EVMPD
SUB07881MIG
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
PRIMARY
PUBCHEM
135398740
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
PRIMARY
DRUG CENTRAL
1277
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
PRIMARY
USAN
W-148
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
PRIMARY
EPA CompTox
DTXSID8041032
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
PRIMARY
DRUG BANK
DB01004
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
PRIMARY
RS_ITEM_NUM
1288306
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
PRIMARY
NCI_THESAURUS
C517
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
PRIMARY
DAILYMED
P9G3CKZ4P5
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
PRIMARY
ChEMBL
CHEMBL182
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
PRIMARY
NSC
759656
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
PRIMARY
RXCUI
4678
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
PRIMARY RxNorm
LACTMED
Ganciclovir
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
PRIMARY
INN
6023
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
PRIMARY
MERCK INDEX
M5663
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
PRIMARY Merck Index
FDA UNII
P9G3CKZ4P5
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
PRIMARY
HSDB
6512
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
PRIMARY
CAS
82410-32-0
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
PRIMARY
MESH
D015774
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
PRIMARY
WIKIPEDIA
GANCICLOVIR
Created by admin on Wed Jul 05 22:36:20 UTC 2023 , Edited by admin on Wed Jul 05 22:36:20 UTC 2023
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
Vmax
TRANSPORTER -> SUBSTRATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
TRANSPORTER -> SUBSTRATE
Km
TRANSPORTER -> SUBSTRATE
Vmax
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
Km
SALT/SOLVATE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.3
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY